MitoBurn®(L-BAIBA,β-aminoisobutyric acid), known as an “exercise factor”, increased levels of L-BAIBA are associated with many of exercise’s numerous benefits. L-BAIBA helps regulate metabolism, increase energy expenditure, manage fuel selection, support the production of ketones, etc.
On October 2, 2022, a research report on Dose-Response Absorption Kinetics of Oral MitoBurn® (L-BAIBA) Supplementation in Healthy Men and Women was published by NNB Nutrition in the Journal of Dietary Supplements. L-BAIBA is a myokine produced in skeletal muscle during exercise and has been shown to impact carbohydrate and fat metabolism in both animals and humans. This study was designed to determine the rate and extent to which MitoBurn® (L-BAIBA) appeared in human plasma after oral ingestion. The result of the experiment is believed to be the first data where the absorption kinetics of acute oral L-BAIBA administration in humans is evaluated.
This experiment was designed as a randomized, double-blind, placebo-controlled, crossover study in healthy males and females. As this was considered a pilot investigation designed to identify the bioavailability of orally ingested L-BAIBA, no formal sample size analysis was completed. Study participants completed five supplementation conditions, at approximately the same time between 0600 − 1000 h, in a crossover fashion with a minimum washout period of 48 h. study participants consumed either a placebo (Tapioca Resistant Dextrin) (PLA), 1500 mg of L-valine (V1500), or 250mg (B250), 500mg (B500), or 1,500mg (B1500) of L-beta-aminoisobutyricacid (Mito Burn®, NNB Nutrition). An online randomization software program (www.random.org) was used to minimize any order effects from testing. Upon arrival for each study visit, participants had their body mass, hydration status, and hemodynamics measured along with an assessment of capillary glucose levels prior to the first blood sample and supplement ingestion to confirm fasting status. Altogether, evidence has mounted to suggest that increases in BAIBA in response to acute and chronic exercise may exert favorable changes in other cardiometabolic tissues.
The purpose of this study was to examine the extent to which orally consumed L-BAIBA at various dosages appears in human circulation. The result showed that (1) the plasma concentration of BAIBA after oral administration of 1500 mg is the highest, which means the highest degree of absorption; (2) There are significant differences between the oral administration of 250, 500 and 1500 mg of BAIBA and the placebo group; (3) The Tmax of 250, 500, and 1500 mg of oral BAIBA was 60 minutes, and the absorption rate was longer than that of the placebo group, but conversely it can be said that the drug effect lasted longer. This study findings support a dose-response increase in L-BAIBA concentration maximum and AUC and was well-tolerated by all study participants. To date, this is the first human trial where bioavailability and safety of oral L-BAIBA consumption was examined. Further, this study may also have been the first investigation to provide L-BAIBA and not a racemic mixture of both enantiomers.